HDAC2 and cancer: Based on our findings linking high HDAC2 expression to adverse outcomes in HCC patients and identifying it as an independent risk factor for HCC, targeting HDAC2 with inhibitors may enhance anticancer strategies by suppressing cancer cell growth and autophagy.